New hope for rare autoimmune disease: eculizumab trial targets relapses
NCT ID NCT06724809
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called eculizumab in Chinese adults with a rare autoimmune disease called NMOSD, which attacks the nerves in the eyes and spinal cord. The goal is to see if the drug can reduce the number of relapses (flare-ups) and slow disability. Participants must have had at least one relapse in the past year and continue their current medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100016, China
-
Research Site
Dongguan, 523059, China
-
Research Site
Jinan, 250012, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Taiyuan, 030001, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wuhan, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study hopes to find a simple test for MS diagnosis
- Massive italian MS registry aims to unlock secrets of the disease
- Silent attacks in NMOSD: new study aims to predict disability before it strikes
- New hope for NMOSD patients: drug aims to slash relapse rate
- New shot aims to stop devastating NMOSD Flare-Ups
- Could a zappy headband cure insomnia in MS patients?